84 related articles for article (PubMed ID: 24863005)
1. KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Lee JS; Shim HS; Chang YS
Lung Cancer; 2014 Aug; 85(2):299-305. PubMed ID: 24863005
[TBL] [Abstract][Full Text] [Related]
2. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
3. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
[TBL] [Abstract][Full Text] [Related]
4. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
[TBL] [Abstract][Full Text] [Related]
6. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.
Peschard P; McCarthy A; Leblanc-Dominguez V; Yeo M; Guichard S; Stamp G; Marshall CJ
Curr Biol; 2012 Nov; 22(21):2063-8. PubMed ID: 23063435
[TBL] [Abstract][Full Text] [Related]
7. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
10. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
13. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
[TBL] [Abstract][Full Text] [Related]
15. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
17. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
[TBL] [Abstract][Full Text] [Related]
19. Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?
Dumenil C; Vieira T; Rouleau E; Antoine M; Duruisseaux M; Poulot V; Lacave R; Cadranel J; Massiani MA; Wislez M
Lung Cancer; 2015 Dec; 90(3):561-7. PubMed ID: 26520186
[TBL] [Abstract][Full Text] [Related]
20. New monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma.
Charkiewicz R; Niklińska W; Zalewski G; Charkiewicz A; Kozlowski M; Sulewska A; Chyczewski L
Adv Med Sci; 2013; 58(1):83-9. PubMed ID: 23729630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
